These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 35227777)
21. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748 [TBL] [Abstract][Full Text] [Related]
22. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821 [TBL] [Abstract][Full Text] [Related]
23. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881 [TBL] [Abstract][Full Text] [Related]
24. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047 [TBL] [Abstract][Full Text] [Related]
25. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227 [TBL] [Abstract][Full Text] [Related]
26. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215 [TBL] [Abstract][Full Text] [Related]
27. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397 [TBL] [Abstract][Full Text] [Related]
29. SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis. Stodtmann S; Chen MJ; Ponce-Bobadilla AV; Finney-Hayward TK; Kalabic J; Mostafa NM Clin Pharmacol Drug Dev; 2024 Sep; 13(9):1033-1043. PubMed ID: 38953600 [TBL] [Abstract][Full Text] [Related]
30. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Feagan BG; Sands BE; Sandborn WJ; Germinaro M; Vetter M; Shao J; Sheng S; Johanns J; Panés J; Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):307-320. PubMed ID: 36738762 [TBL] [Abstract][Full Text] [Related]
31. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358 [TBL] [Abstract][Full Text] [Related]
32. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Zhang ZM; Li W; Jiang XL Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005 [TBL] [Abstract][Full Text] [Related]
36. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Peyrin-Biroulet L; Allegretti JR; Rubin DT; Bressler B; Germinaro M; Huang KG; Shipitofsky N; Zhang H; Wilson R; Han C; Feagan BG; Sandborn WJ; Panés J; Hisamatsu T; Lichtenstein GR; Sands BE; Dignass A; Gastroenterology; 2023 Dec; 165(6):1443-1457. PubMed ID: 37659673 [TBL] [Abstract][Full Text] [Related]